Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 7 (Jul 2007)

Issues

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice

Vangelis G. Manolopoulos

Abstract

Pharmacogenetics and pharmacogenomics deal with genetically determined variations in how individuals respond to drugs. They hold the potential to revolutionize drug therapy. The clinical need for novel approaches to improve pharmacotherapy stems from the high rate of adverse reactions to drugs and their lack of effectiveness in many individuals. Despite the accumulation of research findings showing the potential for clinical benefit for several drug-metabolizing enzymes and some receptors that constitute drug targets, the translation of these findings into tangible clinical applications occurs very slowly. The main steps for clinical implementation of pharmacogenomics include: a) education of clinicians and all other parties involved in the use and benefits of pharmacogenomics; b) execution of large prospective clinical and pharmacoeconomic studies showing the benefit of pharmacogenomic genotyping; c) provision of incentives to develop tests; d) development of specific clinical guidelines; and e) creation of a solid regulatory and ethical framework. Furthermore, the potential should be explored to use existing therapeutic drug monitoring laboratories to introduce pharmacogenomic testing into hospitals. Overall, our thesis is that pharmacogenomics is already a reality in clinical practice and is bound to continue gaining acceptance by clinicians in the coming years.

Clin Chem Lab Med 2007;45:801–14.

Keywords: adverse drug reactions; CYP2D6; CYP2C9; CYP2C19; genetic polymorphism; pharmacogenetics; pharmacogenomics; therapeutic drug monitoring; thiopurine S-methyltransferase (TPMT); uridine diphosphate glucuronosyltransferase (UGT1A1)

About the article

Corresponding author: Dr. Vangelis G. Manolopoulos, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, Greece Phone/Fax: +30-2551-030523


Received: 2007-04-17

Accepted: 2007-05-22

Published in Print: 2007-07-01


Citation Information: Clinical Chemical Laboratory Medicine, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.184.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
Wotan Zeng, Yali Guo, Peixian Chen, Zhike Liu, Dafang Chen, and Chunji Han
Journal of Diabetes Investigation, 2016, Volume 7, Number 5, Page 764
[3]
Chiara Fabbri, Concetta Crisafulli, Marco Calabrò, Edoardo Spina, and Alessandro Serretti
Expert Opinion on Drug Metabolism & Toxicology, 2016, Volume 12, Number 10, Page 1157
[4]
Abdullah M. Alzahrani, Georgia Ragia, Hamza Hanieh, and Vangelis G. Manolopoulos
BioMed Research International, 2013, Volume 2013, Page 1
[5]
Vangelis G Manolopoulos, Georgia Ragia, and Anna Tavridou
Pharmacogenomics, 2011, Volume 12, Number 8, Page 1161
[6]
Georgirene D. Vladutiu
Molecular Genetics and Metabolism, 2008, Volume 93, Number 1, Page 1
[7]
Y. Tony Yang, Elizabeth Wiley, and John Leppard
Journal of Medicine and the Person, 2011, Volume 9, Number 2, Page 48
[8]
O.Y.F. Henry, J. Lluis Acero Sanchez, and C.K. O'Sullivan
Biosensors and Bioelectronics, 2010, Volume 26, Number 4, Page 1500
[9]
Giuseppe Lippi, Massimo Franchini, and Emmanuel J. Favaloro
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 5
[10]
Christian Ensinger and William Sterlacci
Expert Review of Molecular Diagnostics, 2008, Volume 8, Number 2, Page 141
[11]
Georgia Ragia, Ioannis Petridis, Anna Tavridou, Dimitrios Christakidis, and Vangelis G Manolopoulos
Pharmacogenomics, 2009, Volume 10, Number 11, Page 1781
[12]
Georgia Ragia, Kostas I Arvanitidis, Anna Tavridou, and Vangelis G Manolopoulos
Pharmacogenomics, 2009, Volume 10, Number 1, Page 43
[13]
Alessio Squassina, Mirko Manchia, Vangelis G Manolopoulos, Mehmet Artac, Christina Lappa-Manakou, Sophia Karkabouna, Konstantinos Mitropoulos, Maria Del Zompo, and George P Patrinos
Pharmacogenomics, 2010, Volume 11, Number 8, Page 1149
[14]
Philip E. Empey
Critical Care Medicine, 2010, Volume 38, Page S106

Comments (0)

Please log in or register to comment.
Log in